PTC THERAPEUTICS, INC.
PTC THERAPEUTICS, INC. (PTCT): 101 pipeline candidates · 7 upcoming catalysts · ~100 mo cash runway · 18 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
99.6 months
D/E -16.90 · 0% dilution
Lead: Phase 3
101 candidates
7 upcoming, next in ~12d
0 buys · 80 sells (180d)
A transparent, data-derived signal for PTC THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.5B
Cash
$850.4M
Quarterly Burn
$59.0M
Runway
99.6 mo
Revenue
$272.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (101 candidates)
| Drug | Phase |
|---|---|
| [11C]AZ1419 3391 | Phase 1 |
| [177Lu]Lu-DOTA-TATE | Phase 1 |
| [68Ga]Ga-DOTA-TATE | Phase 1 |
| ABBV-155 | Phase 1 |
| ABBV-637 | Phase 1 |
| Apitegromab | Phase 2 |
| Ataluren | Phase 3 |
| AZD9574 | Phase 1 |
| Bleomycin | Phase 1 |
| Bleomycin Sulfate | Phase 3 |
Showing 10 of 101 candidates. Sign up for full pipeline.
Upcoming Catalysts (7)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
351
Total value held
$7.22B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 14,386,866 | $980.0M |
| blackrock, inc. | 12,948,717 | $882.2M |
| rtw investments, lp | 7,746,415 | $527.8M |
| vanguard capital management llc | 7,352,512 | $500.9M |
| vanguard portfolio management llc | 4,804,594 | $327.3M |
| state street corp | 4,346,519 | $296.1M |
| wellington management group llp | 3,942,610 | $268.6M |
| toronto dominion bank | 3,025,963 | $206.2M |
| armistice capital, llc | 2,464,449 | $167.9M |
| geode capital management, llc | 2,209,954 | $150.6M |
Showing top 10 of 351 institutional holders of PTC THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PTC THERAPEUTICS, INC.'s pipeline?
PTC THERAPEUTICS, INC. (PTCT) has 101 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PTC THERAPEUTICS, INC.'s lead drug candidate?
PTC THERAPEUTICS, INC.'s most advanced tracked candidate is [11C]AZ1419 3391 (Phase 1) for Advanced Solid Malignancies (CERTIS1).
What is PTC THERAPEUTICS, INC.'s next catalyst?
PTC THERAPEUTICS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria" — expected June 30, 2026.
What is PTC THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PTC THERAPEUTICS, INC. has approximately 99.6 months of cash runway.
What is PTC THERAPEUTICS, INC.'s market capitalization?
PTC THERAPEUTICS, INC.'s market capitalization is approximately $6.5B.
Get the full picture on PTC THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.